First-in-Human trial of cannabis-based therapy for Parkinson’s initiated

GB Sciences, Inc. is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies…

GB Sciences, Inc. is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson’s disease (“PD”).  The Exploratory IND program is designed to allow the company to make informed, data-driven choices in selecting and prioritising the development of multiple, related drug compositions and formulations. An Exploratory IND requires less pre-clinical data and offers a more flexible way to get essential information about potential drug development candidates than a more conventional early phase development program. Performing an FDA-Registered clinical trial, instead of a Nevada-based pilot trial as reported earlier, also translates to quicker entry into international markets with harmonised

... read more at: https://www.europeanpharmaceuticalreview.com/news/74560/first-in-human-trial-of-cannabis-based-therapy-for-parkinsons-initiated/

by

Leave a Reply

Your email address will not be published. Required fields are marked *